Rebamipid in real clinical practice: quality of life and safety of use-Reference-Cited by-同舟云学术

Rebamipid in real clinical practice: quality of life and safety of use

Published:2021-12-18 Issue:35 Volume: Page:7-11
ISSN:2078-5631
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Babich A. E.¹^ORCID,Luchinina E. V.²^ORCID,Kompaniets O. G.³^ORCID,Zubareva N. A.⁴

Affiliation:

1. Kuban State Medical University; Euromed Clinic

2. Saratov State Medical University n. a. V.I. Razumovsky

3. Kuban State Medical University

4. Kuban State Medical University; Research Institute – Regional Clinical Hospital No. 1 n. a. professor S.V. Ochapovsky

Abstract

The aim of the study was to assess the tolerability and impact on the quality of life of pharmacotherapy for gastric ulcer, erosive gastritis using regimens including rebamipide. The quality of life of patients was assessed using the SF-36 questionnaire. Pharmacotherapy of gastric ulcer with the inclusion of rebamipide as part of the conventional treatment regimen provides data comparable to the healthy group on the scales of physical functioning, role functioning due to physical condition, pain intensity, general health, and vital activity. The results of our own research and data from literary sources indicate that rebamipide is a drug with a confident evidence base, good tolerance and safety of use.

Publisher

Alfmed LLC

Subject

Materials Chemistry,Economics and Econometrics,Media Technology,Forestry

Reference28 articles.

1. Simanenkov V. I., Maev I. V., Tkacheva O. N., Alekseenko S. A., Andreev D. N., Bordin D. S., Vlasov T. D., Vorob’eva N.M., Grinevich V. B., Gubonina I. V., Drobizhev M. Yu., Efremov N. S., Karateev A. E., Kotovskaya Yu.V., Kravchuk Yu.A., Krivoborodov G. G., Kulchavenya E. V., Lila A. M., Mayevskaya M. V., Poluektova E. A., Popkova T. V., Sablin O. A., Solovyeva O. I., Suvorov A. N., Tarasova G. N., Trukhan D. I., Fedotova A. V. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary National Consensus. Cardiovascular therapy and prevention. 2021; 20 (1): 2758. DOI: 10.15829/1728–8800–2021–275.

2. Lai Y, Zhong W, Yu T, Xia Z-S, Li J-Y, Ouyang H, et al. (2015) Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin. PLoS ONE 10(7): e0132031.; Suzuki T, Yoshida N, Nakabe N, et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008; 106 (3): 469–477. DOI: 10.1254/jphs.fp0071422.

3. Hahm KB, Kim DH, Lee KM, et al. Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther. 2003;18 Suppl 1: 24–38. DOI: 10.1046/j.1365–2036.18.s1.3.

4. Kim CD, Kim YK, Lee SH, Hong KW. Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-kappaB-dependent pathway. J Pharmacol Exp Ther. 2000; 294 (3): 864–869.

5. Gasbarrini A. The intestinal barrier in different hystological and pathologcal conditions 2018A. Gudkov et al. Cold Spring Harb Perspect Med. 2016 Nov; 6 (11): a026161